Large-cap medtech has been the worst-performing corner of healthcare over the past year. That is not a footnote. It is the reason these companies will take your meeting.
Large-cap medtech has been the worst-performing corner of healthcare over the past year. That is not a footnote. It is the reason these companies will take your meeting.
Wednesday, July 22, 2026
Wednesday, July 22, 2026
Here is a number that reframes most conversations about innovation partnerships in this sector.
Over the past twelve months, large-cap medical devices have been the weakest part of healthcare. Across the companies we track, twenty-seven of forty beat their own industry benchmark — and only thirteen beat the broad market. Small-cap healthcare, meanwhile, ran well ahead of both.
We are not naming companies here, and we do not name a member as underperforming anywhere. But the shape of it is public, it is consistent, and it matters more to an innovator than any amount of partnership rhetoric.
Why pressure is an opening
An incumbent growing comfortably has limited reason to talk to outsiders. An incumbent absorbing tender-driven price compression, tariff exposure, a quality remediation programme and a portfolio separation at the same time has every reason to.
The corollary is uncomfortable but useful: a company under real pressure is often an excellent pilot partner and a poor sponsorship target. Those are different conversations with different people on different budgets, and confusing them wastes both.
Here is a number that reframes most conversations about innovation partnerships in this sector.
Over the past twelve months, large-cap medical devices have been the weakest part of healthcare. Across the companies we track, twenty-seven of forty beat their own industry benchmark — and only thirteen beat the broad market. Small-cap healthcare, meanwhile, ran well ahead of both.
We are not naming companies here, and we do not name a member as underperforming anywhere. But the shape of it is public, it is consistent, and it matters more to an innovator than any amount of partnership rhetoric.
Why pressure is an opening
An incumbent growing comfortably has limited reason to talk to outsiders. An incumbent absorbing tender-driven price compression, tariff exposure, a quality remediation programme and a portfolio separation at the same time has every reason to.
The corollary is uncomfortable but useful: a company under real pressure is often an excellent pilot partner and a poor sponsorship target. Those are different conversations with different people on different budgets, and confusing them wastes both.
A company under real pressure is often an excellent pilot partner and a poor sponsorship target.
Amplifai analyst desk
Amplifai
A company under real pressure is often an excellent pilot partner and a poor sponsorship target.
Amplifai analyst desk
Amplifai
Where the money is, and where it is not
We model the addressable spend behind each of the fifteen challenges across the twelve largest Asia-Pacific markets. The base is around US$117.7bn of annual medtech spend, derived from published health-expenditure data and a calibrated device share, and validated against three independent anchors that agree within two per cent.
Each individual challenge addresses somewhere between US$1.5bn and US$3.8bn of that a year.
Two things about those numbers that we would rather say ourselves than have pointed out.
They are directional. They are analyst estimates of an addressable share, not forecasts of revenue anybody will book.
They are not additive. One dollar of medtech spend can sit under several challenges at once, so adding the fifteen together produces a number that means nothing. We publish the full method — formula, base layer, sources, calibration — precisely so that a quantitative reader can check the working rather than take the figure on trust.
If you have seen a larger headline figure attached to this programme in the past, this is the number that replaced it, and it is smaller because it is the one we can defend.
Where the money is, and where it is not
We model the addressable spend behind each of the fifteen challenges across the twelve largest Asia-Pacific markets. The base is around US$117.7bn of annual medtech spend, derived from published health-expenditure data and a calibrated device share, and validated against three independent anchors that agree within two per cent.
Each individual challenge addresses somewhere between US$1.5bn and US$3.8bn of that a year.
Two things about those numbers that we would rather say ourselves than have pointed out.
They are directional. They are analyst estimates of an addressable share, not forecasts of revenue anybody will book.
They are not additive. One dollar of medtech spend can sit under several challenges at once, so adding the fifteen together produces a number that means nothing. We publish the full method — formula, base layer, sources, calibration — precisely so that a quantitative reader can check the working rather than take the figure on trust.
If you have seen a larger headline figure attached to this programme in the past, this is the number that replaced it, and it is smaller because it is the one we can defend.
What actually gets funded
Across the cases we have examined, the interventions that got past pilot shared an unglamorous quality: the buyer could point to a line in a budget that improved. Not strategic alignment. Not innovation narrative. A line.
Readmissions avoided. Tonnes diverted. Cases detected. Days of supply protected. Tender eligibility retained.
The capital follows that, eventually. It rarely leads it.
What actually gets funded
Across the cases we have examined, the interventions that got past pilot shared an unglamorous quality: the buyer could point to a line in a budget that improved. Not strategic alignment. Not innovation narrative. A line.
Readmissions avoided. Tonnes diverted. Cases detected. Days of supply protected. Tender eligibility retained.
The capital follows that, eventually. It rarely leads it.
Get the Latest News
Be the first to discover insider tips and the hidden gems of your favorite destinations.
Share This
Get the Latest News
Be the first to discover insider tips and the hidden gems of your favorite destinations.